BriaCell Therapeutics Corp (BCTX)

[Frankestin]

BriaCell has just presented highly encouraging data at ASCO 2025: their Phase 2 results with Bria-IMT™ + checkpoint inhibitor in metastatic breast cancer match or exceed the outcomes of FDA-approved therapies — despite being tested in a more heavily pre-treated population.
Notably, the selected Phase 3 regimen showed a median overall survival of 13.4 months and clinical benefit rate of 61%, outperforming several standard-of-care arms in benchmark studies like ASCENT and TROPiCS-02. Even more compelling: no treatment-related discontinuations were reported.
These results strongly support Bria-IMT’s safety and efficacy, positioning the ongoing pivotal Phase 3 study as a potential pathway to Biologics License Application (BLA) submission with the possibility of Priority Review…